Clinical trial
A Phase I, Randomized, Double-blind, Placebo Controlled, Single Dose Escalation Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors
NCT01921855 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Randomized, Double-blind, Placebo Controlled, Single Dose Escalation Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors
- Lead sponsor
- Bayer
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2009
- Completion date
- December 31, 2009
- Enrollment
- 16 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.